20
P. Srivastava et al. / European Journal of Medicinal Chemistry 65 (2013) 12e20
68Ga-chelate-conjugated bisphosphonate as a bone-seeking agent for PET
4. Conclusion
imaging, Nucl. Med. Biol. 38 (2011) 1011e1018.
[12] I. Lukes, J. Kotek, P. Vojtisek, P. Hermann, Complexes of tetraazacycles bearing
methylphosphinic/phosphonic acid pendant arms with copper(II), zinc(II) and
lanthanides(III). A comparison with their acetic acid analogues, Coord. Chem.
Rev. 216e217 (2001) 287e312.
[13] J.G. Mao, Structures and luminescent properties of lanthanide phosphonates,
Coord. Chem. Rev. 251 (2007) 1493e1520.
[14] A.I. Brenner, J. Koshy, J. Morey, C. Lin, J. DiPoce, The bone scan, Semin. Nucl.
Med. 42 (2012) 11e26.
[15] A. Fontes, M.I.M. Prata, C.F.G.C. Geraldes, J.P. Andre, Ga(III) chelates of
amphiphilic DOTA-based ligands: synthetic route and in vitro and in vivo
studies, Nucl. Med. Biol. 38 (2011) 363e370.
This study demonstrates that removal of one phosphonate
group of DOTP does not affect its ability to act as bone imaging
agent. Instead fourth pendent could be used to make the chelate
bifunctional which, in turn, would increase the scope and efficacy
of the chelate.
A new bifunctional analogue of DOTMP with three methyl
phosphonate groups and one ethyl amine group has been synthe-
sized and its 99mTc complex was prepared. The amine group can
react with many electrophiles like aldehyde, carboxylic acids and
isothiocyanates to form molecules having varying applications as
contrast agent. The synthesis of the amine containing bifunctional
macrocyclic agent was a facile process with simple reaction
conditions.
[16] K. Ogawa, H. Kawashima, K. Shiba, K. Washiyama, M. Yosimoto, Y. Kiyono,
M. Ueda, H. Mori, H. Saji, Development of [90Y]DOTA-conjugated bisphosph-
onate for treatment of painful bone metastases, Nucl. Med. Biol. 36 (2009)
129e135.
[17] K. Ogawa, K. Takai, H. Kanbara, T. Kiwada, Y. Kitamura, K. Shiba, A. Odani,
Preparation and evaluation of
a
radiogallium complex-conjugated
bisphosphonate as a bone scintigraphy agent, Nucl. Med. Biol. 38 (2011)
631e636.
Developed 99mTc-DO3MP-EA has shown ideal biodistribution
characteristics as a bone-imaging-agent. 99mTc-DO3MP-EA is better
in terms of bone to blood ratio as compared to 99mTc-DOTMP.
The complex has shown high serum stability. Biodistribution
studies showed significant bone affinity and renal excretion path
way. Biodistribution studies also proved DO3MP-EA a better
candidate in comparison to DOTMP for theranostics. Stability
studies with Ga showed that it is a potential candidate for PET
applications.
[18] V. Ambrosini, D. Campana, P. Tomassetti, G. Grassetto, D. Rubello, S. Fanti, PET/
CT with 68Gallium-DOTA-peptides in NET: an overview, Eur. J. Radiol. 80
(2010) e116ee119.
[19] V. Kubicek, J. Havlickova, J. Kotek, G. Tircso, P. Hermann, E. Toth, I. Lukes,
Gallium(III) complexes of DOTA and DOTA-monoamide: kinetic and thermo-
dynamic studies, Inorg. Chem. 49 (2010) 10960e10969.
[20] S. Mukherjee, Y. Song, E. Oldfield, NMR investigations of the static and dy-
namic structures of bisphosphonates on human bone: a molecular model,
J. Am. Chem. Soc. 130 (2008) 1264e1273.
[21] S. Mukherjee, C. Huang, F. Guerra, K. Wang, E. Oldfield, Thermodynamics of
bisphosphonates binding to human bone: a two-site model, J. Am. Chem. Soc.
131 (2009) 8374e8375.
[22] H. Schott, D. Goltz, T.C. Schott, C. Jauch, R.A. Schwendener, N4-[Alkyl-
(hydroxyphosphono)phosphonate]-cytidine-new drugs covalently linking
antimetabolites (5-FdU, araU or AZT) with bone-targeting bisphosphonates
(alendronate or pamidronate), Bioorg. Med. Chem. 19 (2011) 3520e3526.
[23] S. Giralt, W. Bensinger, M. Goodman, D. Podoloff, J. Eary, R. Wendt,
R. Alexanian, D. Weber, D. Maloney, L. Holmberg, J. Rajandran, H. Breitz,
R. Ghalie, R. Champlin, 166Ho-DOTMP plus melphalan followed by peripherial
blood stem cell transplantation in patients with multiple myeloma: results in
two phase ½ trials, Blood 102 (2003) 2684e2691.
[24] J. Simon, R.K. Frank, D.K. Crump, W.D. Erwin, N.T. Ueno, R.E. Wendt III,
A preclinical investigation of the saturation and dosimetry of 153Sm-DOTMP
as a bone-seeking radiopharmaceutical, Nucl. Med. Biol. 39 (2012) 770e776.
[25] Z. Piskula, I. Svobodova, P. Lubal, S. Lis, Z. Hnatejko, P. Hermann, Kinetic study
References
[1] J.L. Tremoleda, M. Khalil, L.L. Gompels, M.W. Arridge, T. Vincent, W. Gsell,
Imaging technologies for preclinical models of bone and joint disorders, Eur. J.
Nucl. Med. Mol. Imaging Res. 1 (2011) 1e14.
[2] J. Galezowska, E.G. Kontecka, Phosphonates, their complexes and bio-
applications:
(2012) 105e124.
a spectrum of surprising diversity, Coord. Chem. Rev. 256
[3] R.E. Mewis, S.J. Archibald, Biomedical applications of macrocyclic ligand
complexes, Coord. Chem. Rev. 254 (2010) 1686e1712.
[4] C. Rill, Z.I. Kolar, G. Kickelbick, H.T. Wolterbeek, J.A. Peters, Kinetics and
thermodynamics of adsorption on hydroxyapatite of [160Tb]Terbium com-
plexes of the bone-targeting ligands DOTP and BPPED, Langmuir 25 (2009)
2294e2301.
[5] W.R. Harris, L. Messori, A comparative study of aluminium(III), gallium(III),
indium(III), and thallium(III) binding to human serum transferrin, Coord.
Chem. Rev. 228 (2002) 237e262.
[6] A.D. Sa, M.I.M. Prata, C.F.G.C. Geraldes, J.P. Andre, Triaza-based amphiphilic
chelators: synthetic route, in vitro characterization and in vivo studies of their
Ga(III) and Al(III) chelates, J. Inorg. Biochem. 104 (2010) 1051e1062.
[7] H.J. Kim, D.Y. Kim, J.H. Park, S.D. Yang, M.G. Hur, J.J. Min, K.H. Yu, Synthesis and
characterization of a 68Ga-labelled N-(2-diethylaminoethyl)benzamide de-
rivative as potential PET probe for malignant melanoma, Bioorg. Med. Chem.
20 (2012) 4915e4920.
of dissociation of Eu(III) complex with H8dotp (H8dotp
tetraazacyclododecane-1,4,7,10-tetrakis(methylphosphonic acid)), Inorg.
Chim. Acta 360 (2007) 3748e3755.
¼
1,4,7,10-
[26] I. Svobodova, Z. Piskula, P. Lubal, S. Lis, P. Hermann, Dissociation kinetics study
of Ce(III) complexes with H8dotp (H8dotp ¼ 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetrakis(methylphosphonic acid)), J. Alloys Compd. 451 (2008) 42e45.
[27] Q.Q. Hoang, F. Sicheri, A.J. Howard, D.S.C. Yang, Bone recognition mechanism
of porcine osteocalcin from crystal structure, Nature 425 (2003) 977e980.
[28] T. Vitha, V. Kubicek, P. Hermann, Z.I. Kolar, H.T. Wolterbeek, J.A. Peters,
I. Lukes, Complexes of DOTA-bisphosphonate conjugates: probes for deter-
mination of absorption capacity and affinity constants of hydroxyapatite,
Langmuir 24 (2008) 1952e1958.
[29] A. Datta, P. Panwar, K. Chuttani, A.K. Mishra, Synthesis of 99mTc-DOTMP and
its preclinical evaluation as a multidentate imaging agent for skeletal me-
tastases, Cancer Biother. Radiopharm. 24 (2008) 123e128.
[8] G.M. Blake, S.J.P. Holohan, G.J.R. Cook, I. Fogelman, Quantitative studies of
bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate, Semin.
Nucl. Med. 31 (2001) 28e49.
[30] P. Panwar, S. Singh, N. Kumar, H. Rawat, A.K. Mishra, Synthesis, character-
ization and in vivo skeletal localization of a new 99mTc-based multidentate
phosphonate chelate: 5-amino-1,3-bis(ethylamine-(N, N-dimethyl diphos-
phonic acid)acetamido) benzene, Bioorg. Med. Chem. 15 (2007) 1138e1145.
[31] A.A. El-Mabhouh, C.A. Angelov, R. Cavell, J.R. Mercer, A 99mTc-labeled gemcitabine
bisphosphonate drug conjugate as a probe to assess the potential for targeted
chemotherapy of metastatic bone cancer, Nucl. Med. Biol. 33 (2006) 715e722.
[9] K. Ogawa, H. Saji, Advances in drug design of radiometal-based imaging
agents for bone disorders, Int. J. Mol. Imaging (2011) 7. Article ID 537687.
[10] M. Fellner, B. Biesalski, N. Bausbacher, V. Kubicek, P. Hermann, F. Rosch,
O. Thews, 68Ga-BPAMD: PET-imaging of bone metastases with a generator
based positron emitter, Nucl. Med. Biol. 39 (2012) 993e999.
[11] K. Suzuki, M. Satake, J. Suwada, S. Oshikiri, H. Ashino, H. Dozono,
A. Hino, H. Kasahara, T. Minamizawa, Synthesis and evaluation of a novel